Generic drug
Adalimumab price, strengths & recalls
Generic of Humira, Hadlima, Simlandi, Yusimry, Yuflyma
Pharmacies pay $490.68 for 1 kit of Adalimumab 100 mg/mL, 0.4 mL auto-injector this week, and from $490.68 to $1,278.82 across its 6 priced strengths and forms. 5 manufacturers make it. It has 2 recalls on record, none ongoing. Its official label last changed on July 9, 2026.
Generic- Fair cash price
- $574.78
- Strengths
- 6
- Makers
- 5
- Updated
- Nov 11
Adalimumab price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 50 mg/mL, 0.8 mL auto-injector | $872.64 | $872.64 / 1 kit |
| 50 mg/mL, 0.8 mL auto-injector | $639.41 | $1,278.82 / 2 kits |
| 100 mg/mL, 0.4 mL auto-injector | $490.68 | $490.68 / 1 kit |
| 100 mg/mL, 0.4 mL auto-injector | $1,589.40 | $1,271.52 / 0.8 mL |
| 100 mg/mL, 0.4 mL auto-injector | $638.98 | $1,277.95 / 2 kits |
| 100 mg/mL, 0.4 mL prefilled syringe | $489.09 | $978.19 / 2 kits |
Brand names of adalimumab
A brand and its generic share the active ingredient; the generic is almost always far cheaper.
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Adalimumab
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use ADALIMUMAB-AATY safely and effectively. See full prescribing information for ADALIMUMAB-AATY. ADALIMUMAB-AATY injection, for subcutaneous use Initial U.S. Approval: 2023This product is YUFLYMA (adalimumab-aaty). Adalimumab-aaty is biosimilar* to HUMIRA (adalimumab).
WARNING: SERIOUS INFECTIONS and MALIGNANCY
WARNING: SERIOUS INFECTIONS and MALIGNANCY
See full prescribing information for complete boxed warning.
SERIOUS INFECTIONS (5.1, 6.1):
Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens.
Discontinue Adalimumab-aaty if a patient develops a serious infection or sepsis during treatment.
Perform test for latent TB; if positive, start treatment for TB prior to starting Adalimumab-aaty.
Monitor all patients for active TB during treatment, even if initial latent TB test is negative.
MALIGNANCY (5.2):
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products.
Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products.
SERIOUS INFECTIONS
Patients treated with adalimumab products, including Adalimumab-aaty, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1)]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
Discontinue Adalimumab-aaty if a patient develops a serious infection or sepsis.
Reported infections include:
Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before Adalimumab-aaty use and during therapy. Initiate treatment for latent TB prior to Adalimumab-aaty use.
Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.
Carefully consider the risks and benefits of treatment with Adalimumab-aaty prior to initiating therapy in patients with chronic or recurrent infection.
Monitor patients closely for the development of signs and symptoms of infection during and after treatment with Adalimumab-aaty, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].
MALIGNANCY
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products [see Warnings and Precautions (5.2)]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6-MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2)].
Recent major changes (as listed on the label)
RECENT MAJOR CHANGES
Indications and Usage, Hidradenitis Suppurativa (1.8) | 10/2025 |
Indications and Usage, Uveitis (1.9) | 10/2025 |
Dosage and Administration, Recommended Dosage in Juvenile Idiopathic Arthritis or Pediatric Uveitis (2.3) | 10/2025 |
Dosage and Administration, Recommended Dosage in Hidradenitis Suppurativa (2.7) | 10/2025 |
Warnings and Precautions, Autoimmunity (5.9) | 10/2025 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- BLA761058 · Boehringer Ingelheim
- First approved
- August 25, 2017 (9 years ago)
- Latest approved change
- October 16, 2025
- Approved label
- PDF, Oct 22, 2025
- Generic makers
- None on the market
Adalimumab questions
How much does adalimumab cost without insurance?
Pharmacies pay about $490.68 for 1 kit of adalimumab 100 mg/mL, 0.4 mL auto-injector ($490.68 per unit). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $574.78. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
What is the brand name of adalimumab?
Is adalimumab in shortage?
No shortage is reported for adalimumab right now. We check the national shortage list every day.
Has adalimumab been recalled?
2 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the adalimumab label last change?
The official label was last updated on July 9, 2026 (version 7). See what changed.
Talk about adalimumab
No comments yet. Questions, tips, what worked for you - start the conversation.